References
- Whatley AD , DiIorioCK, YeagerK. Examining the relationships of depressive symptoms, stigma, social support and regimen-specific support on quality of life in adult patients with epilepsy. Health Educ. Res25(4), 575–584 (2010).
- Stafstrom CE . Epilepsy: a review of selected clinical syndromes and advances in basic science. J. Cereb. Blood Flow Metab.26(8), 983–1004 (2006).
- de Boer HM , MulaM, SanderJW. The global burden and stigma of epilepsy. Epilepsy Behav.12(4), 540–546 (2008).
- Engel J Jr . Progress in epilepsy: reducing the treatment gap and the promise of biomarkers. Curr. Opin. Neurol.21(2), 150–154 (2008).
- Laxer KD , TrinkaE, HirschLJet al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav.37, 59–70 (2014).
- Engelborghs S , D'HoogeR, De DeynPP. Pathophysiology of epilepsy. Acta Neurol. Belg.100(4), 201–213 (2000).
- Friedman A , DingledineR. Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia52(Suppl. 3), 33–39 (2011).
- Vezzani A , GranataT. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia46(11), 1724–1743 (2005).
- Guieu R , MesdjianE, RochatH, RogerJ. Central analgesic effect of valproate in patients with epilepsy. Seizure2(2), 147–150 (1993).
- Guieu R , MesdjianE, RogerJ, DanoP, PougetJ, SerratriceG. Nociceptive threshold in patients with epilepsy. Epilepsy Res.12(1), 57–61 (1992).
- Kudoh A , MatsukiA. Current perception thresholds of epileptic patients treated with valproate. Seizure9(7), 498–501 (2000).
- Selim MM , Wendelschafer-CrabbG, HodgesJSet al. Variation in quantitative sensory testing and epidermal nerve fiber density in repeated measurements. Pain151(3), 575–581 (2010).
- Rolke R , MagerlW, CampbellKAet al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur. J. Pain10(1), 77–88 (2006).
- Ximenes JC , de Oliveira GoncalvesD, SiqueiraRMet al. Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch. Pharmacol.386(7), 575–587 (2013).
- Gill D , DerryS, WiffenPJ, MooreRA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. (10), CD009183 (2011).
- Linde M , MullenersWM, ChronicleEP, McCroryDC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev.6, CD010611 (2013).
- Turner K , PiazziniA, FranzaA, CangerR, CaneviniMP, MarconiAM. Do women with epilepsy have more fear of childbirth during pregnancy compared with women without epilepsy? A case–control study. Birth35(2), 147–152 (2008).
- Coimbra NC , FreitasRL, SavoldiMet al. Opioid neurotransmission in the post-ictal analgesia: involvement of mu(1)-opioid receptor. Brain Res.903(1–2), 216–221 (2001).
- Coimbra NC , Castro-SouzaC, SegatoENet al. Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms. Brain Res.888(2), 314–320 (2001).
- Mares J , RokytaR. Algesthesia after epileptic seizure. Physiol Res.58(2), 279–285 (2009).
- Modir JG , WallaceMS. Human experimental pain models 2: the cold pressor model. Methods Mol. Biol.617, 165–168 (2010).
- Polianskis R , Graven-NielsenT, Arendt-NielsenL. Modality-specific facilitation and adaptation to painful tonic stimulation in humans. Eur. J. Pain6(6), 475–484 (2002).
- Scharfman HE . Brain-derived neurotrophic factor and epilepsy – a missing link?Epilepsy Curr.5(3), 83–88 (2005).
- Aronica E , LeenstraS, JansenGH, van VeelenCW, YankayaB, TroostD. Expression of brain-derived neurotrophic factor and tyrosine kinase B receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocalization with N-methyl-D-aspartic acid receptor. Acta Neuropathol.101(4), 383–392 (2001).
- Binder DK . The role of BDNF in epilepsy and other diseases of the mature nervous system. Adv. Exp. Med. Biol.548, 34–56 (2004).
- Connolly AM , ChezM, StreifEMet al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol. Psychiatry59(4), 354–363 (2006).
- LaFrance WC Jr , LeaverK, StopaEG, PapandonatosGD, BlumAS. Decreased serum BDNF levels in patients with epileptic and psychogenic nonepileptic seizures. Neurology75(14), 1285–1291 (2010).
- Hong Z , LiW, QuBet al. Serum brain-derived neurotrophic factor levels in epilepsy. Eur. J. Neurol.21(1), 57–64 (2014).
- Zhu WJ , RoperSN. Brain-derived neurotrophic factor enhances fast excitatory synaptic transmission in human epileptic dentate gyrus. Ann. Neurol.50(2), 188–194 (2001).
- Koyama R , IkegayaY. To BDNF or not to BDNF: that is the epileptic hippocampus. Neuroscientist11(4), 282–287 (2005).
- Wang FJ , LiCM, HouXH, WangXR, ZhangLM. Selective upregulation of brain-derived neurotrophic factor (BDNF) transcripts and BDNF direct induction of activity independent N-methyl-D-aspartate currents in temporal lobe epilepsy patients with hippocampal sclerosis. J. Int. Med. Res.39(4), 1358–1368 (2011).
- Tanaka T , SaitoH, MatsukiN. Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. J. Neurosci.17(9), 2959–2966 (1997).
- Pan W , BanksWA, FasoldMB, BluthJ, KastinAJ. Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology37(12), 1553–1561 (1998).
- Ferrini F , De KoninckY. Microglia control neuronal network excitability via BDNF signalling. Neural. Plast.2013, 429815 (2013).
- Lemos C , MendoncaD, Pereira-MonteiroJet al. BDNF and CGRP interaction: implications in migraine susceptibility. Cephalalgia30(11), 1375–1382 (2010).
- Coull JA , BeggsS, BoudreauDet al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature438(7070), 1017–1021 (2005).
- Zhang X , WangJ, ZhouQet al. Brain-derived neurotrophic factor-activated astrocytes produce mechanical allodynia in neuropathic pain. Neuroscience199, 452–460 (2011).
- Neeb L , HellenP, BoehnkeCet al. IL-1β stimulates COX-2 dependent PGE2 synthesis and CGRP release in rat trigeminal ganglia cells. PLoS ONE6(3), e17360 (2011).
- Papetti L , NicitaF, ParisiP, SpaliceA, VillaMP, Kasteleijn-Nolst TreniteDG. “Headache and epilepsy” – how are they connected?Epilepsy Behav.26(3), 386–393 (2013).
- Saria A , MarksteinerJ, HumpelC, SperkG. Pronounced increases in brain levels of calcitonin gene-related peptide after kainic acid induced seizures. Regul. Pept.26(3), 215–223 (1989).
- Pierce JP , PunsoniM, McCloskeyDP, ScharfmanHE. Mossy cell axon synaptic contacts on ectopic granule cells that are born following pilocarpine-induced seizures. Neurosci. Lett.422(2), 136–140 (2007).
- Buldyrev I , TannerNM, HsiehHY, DoddEG, NguyenLT, BalkowiecA. Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J. Neurochem.99(5), 1338–1350 (2006).
- Kawabata A . Prostaglandin E2 and pain – an update. Biol. Pharm. Bull.34(8), 1170–1173 (2011).
- Vezzani A , FriedmanA, DingledineRJ. The role of inflammation in epileptogenesis. Neuropharmacology69, 16–24 (2013).
- Tutuncuoglu S , KutukculerN, KepeL, CokerC, BerdeliA, TekgulH. Proinflammatory cytokines prostaglandins and zinc in febrile convulsions. Pediatr. Int.43(3), 235–239 (2001).
- Al-Shorbagy MY , El SayehBM, AbdallahDM. Additional antiepileptic mechanisms of levetiracetam in lithium-pilocarpine treated rats. PLoS ONE8(10), e76735 (2013).
- Zhang Z , ZhangZY, FauserU, SchluesenerHJ. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol. Life Sci.65(24), 4055–4065 (2008).
- Zheng Q , LiuW, LiuZ, ZhaoH, HanX, ZhaoM. Valproic acid protects septic mice from renal injury by reducing the inflammatory response. J. Surg. Res.192(1), 163–169 (2014).
- Kacinski M , BudziszewskaB, LasonWet al. Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol. Rep.64(6), 1427–1433 (2012).
- Rothermundt M , PetersM, PrehnJH, AroltV. S100B in brain damage and neurodegeneration. Microsc. Res. Tech.60(6), 614–632 (2003).
- Infante JR , Torres-AvisbalM, MartinezAet al. Evaluation of tumor marker S-100 in cerebrospinal fluid from subjects with nonischemic brain pathologies. Tumour Biol.21(1), 38–45 (2000).
- Gao F , HarrisDN, Sapsed-ByrneS, StandfieldNJ. Nerve tissue protein S-100 and neurone-specific enolase concentrations in cerebrospinal fluid and blood during carotid endarterectomy. Anaesthesia55(8), 764–769 (2000).
- Schmidt H , GerberJ, StuertzKet al. S100B in the cerebrospinal fluid – a marker for glial damage in the rabbit model of pneumococcal meningitis. Neurosci. Lett.475(2), 104–107 (2010).
- Calik M , AbuhandanM, SonmezlerAet al. Elevated serum S-100B levels in children with temporal lobe epilepsy. Seizure22(2), 99–102 (2013).
- Reiber H . Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta310(2), 173–186 (2001).
- Stocchero CM , OsesJP, CunhaGSet al. Serum S100B level increases after running but not cycling exercise. Appl. Physiol. Nutr. Metab.39(3), 340–344 (2014).
- Teepker M , MunkK, MyliusVet al. Serum concentrations of s100b and NSE in migraine. Headache49(2), 245–252 (2009).
- Papandreou O , SoldatouA, TsitsikaAet al. Serum S100beta protein in children with acute recurrent headache: a potentially useful marker for migraine. Headache45(10), 1313–1316 (2005).
- Yilmaz N , KaraaliK, OzdemS, TurkayM, UnalA, DoraB. Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration?Cell Mol. Neurobiol.31(4), 579–585 (2011).
- Zanette SA , Dussan-SarriaJA, SouzaA, DeitosA, TorresIL, CaumoW. Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol. Pain10(46), 1–9 (2014).
- Pfeffer K . Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev.14(3–4), 185–191 (2003).
- Sade-Feldman M , KantermanJ, Ish-ShalomE, ElnekaveM, HorwitzE, BaniyashM. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity38(3), 541–554 (2013).
- Pickering M , O'ConnorJJ. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog. Brain Res.163, 339–354 (2007).
- Balosso S , MarosoM, Sanchez-AlavezMet al. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain131(Pt 12), 3256–3265 (2008).
- Bauer S , CepokS, Todorova-RudolphAet al. Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res.86(1), 82–88 (2009).
- Guenther S , BauerS, HaggeMet al. Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans. Seizure23(8), 666–669 (2014).
- Sonmez FM , SerinHM, AlverAet al. Blood levels of cytokines in children with idiopathic partial and generalized epilepsy. Seizure22(7), 517–521 (2013).
- Rozen T , SwidanSZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache47(7), 1050–1055 (2007).
- Kondrusik M , Hermanowska-SzpakowiczT. [The assessment of tumor necrosis factor (TNF) alpha and interleukin (IL)-1 beta levels in cerebrospinal fluid (CSF) and serum in patients with purulent meningitis]. Neurol. Neurochir. Pol.31(6), 1119–1131 (1997).